BeiGene Capital Surpluse from 2010 to 2024

BGNE Stock  USD 215.00  8.84  4.29%   
BeiGene's Capital Surpluse is increasing over the years with slightly volatile fluctuation. Overall, Capital Surpluse is expected to go to about 13.5 B this year. During the period from 2010 to 2024 BeiGene Capital Surpluse annual values regression line had geometric mean of  497,302,607 and mean square error of 5810433.3 T. View All Fundamentals
 
Capital Surpluse  
First Reported
2016-03-31
Previous Quarter
11.4 B
Current Value
11.5 B
Quarterly Volatility
3.8 B
 
Yuan Drop
 
Covid
Check BeiGene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BeiGene's main balance sheet or income statement drivers, such as Depreciation And Amortization of 92.1 M, Interest Expense of 39.2 M or Selling General Administrative of 1.5 B, as well as many indicators such as Price To Sales Ratio of 7.27, Dividend Yield of 0.0 or PTB Ratio of 4.02. BeiGene financial statements analysis is a perfect complement when working with BeiGene Valuation or Volatility modules.
  
Check out the analysis of BeiGene Correlation against competitors.
For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.

Latest BeiGene's Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of BeiGene over the last few years. It is BeiGene's Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BeiGene's overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

BeiGene Capital Surpluse Regression Statistics

Arithmetic Mean4,236,790,067
Geometric Mean497,302,607
Coefficient Of Variation126.46
Mean Deviation4,666,105,956
Median1,000,747,000
Standard Deviation5,357,798,339
Sample Variance28706003T
Range13.5B
R-Value0.90
Mean Square Error5810433.3T
R-Squared0.81
Slope1,079,597,164
Total Sum of Squares401884042.6T

BeiGene Capital Surpluse History

202413.5 B
202312.9 B
202111.2 B
20207.4 B
20192.9 B
20182.7 B
2017B

About BeiGene Financial Statements

BeiGene stakeholders use historical fundamental indicators, such as BeiGene's Capital Surpluse, to determine how well the company is positioned to perform in the future. Although BeiGene investors may analyze each financial statement separately, they are all interrelated. For example, changes in BeiGene's assets and liabilities are reflected in the revenues and expenses on BeiGene's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in BeiGene. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Surpluse12.9 B13.5 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether BeiGene is a strong investment it is important to analyze BeiGene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BeiGene's future performance. For an informed investment choice regarding BeiGene Stock, refer to the following important reports:
Check out the analysis of BeiGene Correlation against competitors.
For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BeiGene. If investors know BeiGene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BeiGene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.19)
Revenue Per Share
225.239
Quarterly Revenue Growth
0.395
Return On Assets
(0.1)
Return On Equity
(0.23)
The market value of BeiGene is measured differently than its book value, which is the value of BeiGene that is recorded on the company's balance sheet. Investors also form their own opinion of BeiGene's value that differs from its market value or its book value, called intrinsic value, which is BeiGene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BeiGene's market value can be influenced by many factors that don't directly affect BeiGene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BeiGene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BeiGene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BeiGene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.